We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




PCR Screening and Typing, Toolset Expanded for Ebolavirus

By LabMedica International staff writers
Posted on 19 Aug 2014
Print article
Image: Colorized transmission electron micrograph (TEM) revealing some of the ultrastructural morphology of an Ebolavirus virion (Image courtesy of Cynthia Goldsmith and the US Centers for Disease Control and Prevention (USA; CDC ref# PHIL 1832), via Wikimedia Commons).
Image: Colorized transmission electron micrograph (TEM) revealing some of the ultrastructural morphology of an Ebolavirus virion (Image courtesy of Cynthia Goldsmith and the US Centers for Disease Control and Prevention (USA; CDC ref# PHIL 1832), via Wikimedia Commons).
A new real-time polymerase chain reaction (RT-PCR)-based assay for identification of the five Ebolavirus species and Marburgvirus has been added to the Ebolavirus diagnostics toolset.

altona Diagnostics, GmbH (Hamburg, Germany), focused on the development, approval, manufacturing, and marketing of molecular diagnostic test systems for the detection and quantification of pathogens, has added a real-time RT-PCR-based assay, the RealStar Filovirus type RT-PCR kit, for identification of the five known Ebolavirus species and of Marburgvirus to their product portfolio. In addition to other activities, altona Diagnostics was also among the first to make reliable diagnostic kits commercially available during outbreaks for severe acute respiratory syndrome (SARS), avian Flu, swine Flu, and enterohemorrhagic Escherichia coli (EHEC).

Together with their already existing RealStar Filovirus Screen RT-PCR kit for first-line analysis, which is currently being used in the epidemic epicenter in West-Africa by the European Mobile Laboratory, altona Diagnostics now offers a comprehensive assay family for the detection and characterization of filovirus RNA from human sample material. While the screen kit detects all five Ebolavirus species without differentiation, as well as Marburgvirus, the typing kit is meant to be used as a second-line assay for confirmation of positive results and to distinguish between the five Ebolavirus species as well as Marburgvirus. Both kits are compatible with various real-time PCR platforms.

“For us, in the current situation during this epidemic outbreak, it´s more relevant that we were able to come up with a ready-to-use first-line test kit for filoviruses , which is now used in Guinea and Nigeria to identify infected patients and which is stocked by several European reference institutions under their preparedness plans,” said Dr. Markus Hess, chief scientific officer of altona Diagnostics, “The characterization of a positive sample by using the RealStar Filovirus type RT-PCR kit for Ebola and Marburgvirus is more of epidemiological and scientific importance.”

The ready-to-use real-time PCR kits for screening and typing of filoviruses are available as research use only reagents, currently. The In-Vitro Diagnostic (IVD) CE-marked version of the RealStar Filovirus Screen RT-PCR Kit will be available in September 2014.

Related Links:

altona Diagnostics
RealStar Filovirus RT-PCR kits


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.